Last reviewed · How we verify

DC — Competitive Intelligence Brief

DC (DC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: dopamine agonist. Area: Neurology.

marketed dopamine agonist dopamine receptor Neurology Biologic Live · refreshed every 30 min

Target snapshot

DC (DC) — Gary Archer Ph.D.. DC is a dopamine agonist that acts on dopamine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DC TARGET DC Gary Archer Ph.D. marketed dopamine agonist dopamine receptor
Barhemsys AMISULPRIDE Acacia marketed Dopamine-2 Receptor Antagonist [EPC] D(2) dopamine receptor 2020-01-01
Rexulti BREXPIPRAZOLE Otsuka marketed Atypical Antipsychotic [EPC] D(2) dopamine receptor 2015-01-01
Vraylar CARIPRAZINE AbbVie marketed Atypical Antipsychotic [EPC] D(3) dopamine receptor 2015-01-01
Aristada ARIPIPRAZOLE LAUROXIL Alkermes Inc marketed D(2) dopamine receptor 2015-01-01
Lonasen BLONANSERIN Dainippon Sumitomo Pharma Co., Ltd. marketed blonanserin D(2) dopamine receptor 2008-01-01
Nuvigil ARMODAFINIL Nuvo Pharms marketed armodafinil D(2) dopamine receptor 2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (dopamine agonist class)

  1. GlaxoSmithKline · 3 drugs in this class
  2. Gary Archer Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DC — Competitive Intelligence Brief. https://druglandscape.com/ci/dc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: